Invion Reports 79% Disease Control in Phase 1 Skin Cancer Trial
Invion closed Phase 1 recruitment in non-melanoma skin cancer, reporting 79% disease control across 14 patients — an early signal now awaiting full data readout.
Topic
Invion
Topic
Topic
Topic
Invion closed Phase 1 recruitment in non-melanoma skin cancer, reporting 79% disease control across 14 patients — an early signal now awaiting full data readout.